LENZ Therapeutics (NASDAQ:LENZ) Announces Earnings Results

LENZ Therapeutics (NASDAQ:LENZ) posted its quarterly earnings results on Wednesday. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04), Zacks reports.

LENZ Therapeutics Stock Performance

NASDAQ LENZ opened at $26.30 on Friday. LENZ Therapeutics has a 1-year low of $14.42 and a 1-year high of $38.93. The business has a 50 day simple moving average of $24.09 and a two-hundred day simple moving average of $27.01.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. TD Cowen started coverage on LENZ Therapeutics in a research report on Tuesday. They set a “buy” rating and a $60.00 target price for the company. Citigroup increased their price objective on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a report on Thursday. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, LENZ Therapeutics presently has an average rating of “Buy” and a consensus target price of $41.67.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.